FDA Approved: ORLADEYO — Original Application (BioCryst Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves ORLADEYO (berotralstat hydrochloride) from BioCryst as an oral prophylaxis to prevent attacks of hereditary angioedema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ORLADEYO (berotralstat hydrochloride)

Snippet

ORIG AP for ORLADEYO (BEROTRALSTAT HYDROCHLORIDE)